The AKI-to-CKD Transition

By the end of this chapter you should be able to:

• Classify recovery after AKI as complete, partial, or non-recovery, and place a patient on the AKI-AKD-CKD continuum.
• Explain why AKI is an independent risk factor for CKD, ESKD, cardiovascular disease, and death, even after apparent recovery.
• Describe the maladaptive-repair mechanisms that drive the AKI-to-CKD transition.
• Identify the patients at highest risk of transition and target them for follow-up.
• Assess readiness to wean from dialysis and avoid both premature discontinuation and unnecessary continuation.
• Deliver the post-AKI survivorship bundle: structured follow-up, blood-pressure and proteinuria control, and nephrotoxin avoidance.
• Reconcile medications after AKI — restarting RAAS blockade appropriately and avoiding re-exposure to the culprit.
• Counsel the survivor on AKI as a lasting risk marker, including sick-day rules and contrast caution.

• AKI does not simply resolve or kill; survivors follow a trajectory to complete recovery, partial recovery, dialysis dependence, or progressive CKD.
• Recovery is complete (back to baseline), partial (improved but not baseline), or absent (persistent dysfunction or dialysis dependence), and AKI can also recur.
• Acute kidney disease — the 7-to-90-day convalescent window — is where the trajectory is decided and where follow-up matters most.
• AKI is an independent risk factor for incident and progressive CKD, ESKD, cardiovascular disease, and death — even a single episode with apparent full recovery raises long-term risk.
• Risk rises with AKI severity, duration, and recurrence, with incomplete recovery, and with pre-existing CKD, diabetes, age, and proteinuria.
• The transition is driven by maladaptive repair: tubular cells that fail to redifferentiate become persistent profibrotic signallers.
• Cell-cycle arrest in G2/M, stress-induced cellular senescence with its secretory phenotype, and epigenetic reprogramming lock cells into a fibrogenic state.
• Capillary rarefaction causes chronic hypoxia, and nephron loss drives hyperfiltration of survivors — together producing interstitial fibrosis, tubular atrophy, and glomerulosclerosis.
• Weaning from dialysis is guided by rising urine output and recovering clearance; avoid stopping too early (relapse) or continuing unnecessarily (dependence).
• Many AKI survivors are never followed up — a major care gap, since the kidney attack has long-term consequences.
• KDIGO recommends evaluation around three months for resolution, recurrence, and new or progressive CKD, with nephrology follow-up for severe, dialysis-requiring, recurrent, or incompletely recovered AKI.
• Slow progression with blood-pressure control, proteinuria reduction, judicious RAAS blockade, nephrotoxin avoidance, and cardiovascular risk management — the bridge to the CKD volume.
• Reconcile medications: restart RAAS blockade once recovered and stable, avoid re-exposure to the culprit nephrotoxin, and adjust doses to recovered function.
• No drug yet prevents the transition in humans; survivorship care, not a pill, is the evidence-based intervention.

An episode of AKI ends in one of four ways, not two. The patient does not simply recover or die; the survivor enters a convalescence that may return them to baseline, leave them with residual disease, make them dialysis-dependent, or set them on a slow march to chronic kidney disease. That last path — the AKI-to-CKD transition — is the reason AKI matters long after the hospital stay, and the reason every survivor deserves follow-up. The mechanisms are increasingly understood, the consequences are serious, and the care that mitigates them is, for now, supportive rather than pharmacological.

Four trajectories, one convalescent window

Recovery after AKI is not binary. Some patients return completely to their baseline creatinine; others recover partially, settling at a new, worse baseline; others do not recover and remain dialysis-dependent; and many will have a further episode, because AKI begets AKI. The framework that organises this is the continuum from Chapter 1: AKI in the first seven days, acute kidney disease from seven to ninety days, and chronic kidney disease beyond ninety. Acute kidney disease is the crucial middle zone — the convalescence during which the trajectory is still being decided and during which follow-up can change the outcome. It was named precisely to stop these patients from disappearing in the gap between the acute ward and any clinic.

Why AKI matters beyond the admission

The central epidemiological fact is that AKI is an independent risk factor for the long-term outcomes that matter: incident and progressive chronic kidney disease, end-stage kidney disease, cardiovascular disease, and death. This holds after adjustment for the comorbidities that accompany AKI, and — strikingly — it holds even for patients whose creatinine appears to return fully to baseline, because apparent biochemical recovery can mask a kidney with reduced reserve and ongoing maladaptive repair. The risk is graded: it rises with the severity of the AKI, with its duration, with each recurrence, and with incomplete recovery, and it is amplified by pre-existing CKD, diabetes, older age, and proteinuria. The practical consequence is unambiguous — an AKI episode is a lasting risk marker, a kidney attack, and the survivor is not the same as someone who never had one.

The maladaptive repair that drives the transition

After tubular injury, the kidney attempts repair, and the fork between adaptive and maladaptive repair determines the outcome. In adaptive repair, surviving tubular cells dedifferentiate, proliferate, and then redifferentiate into a normal epithelium — recovery. In maladaptive, or failed, repair, a population of cells survives but never completes redifferentiation. These failed-repair tubular cells persist in a dedifferentiated, pro-inflammatory, pro-fibrotic state, secreting profibrotic mediators — transforming growth factor beta and the developmental signalling pathways reactivated in injury — that drive the interstitium toward fibrosis. They are not bystanders; they are signalling factories for chronic disease.

Several interlocking processes sustain this state. Injured tubular cells arrested in the G2/M phase of the cell cycle become profibrotic secretors rather than dividing normally. Stress-induced cellular senescence accumulates senescent cells expressing their characteristic markers, which broadcast a senescence-associated secretory phenotype of inflammatory and fibrogenic signals. Epigenetic reprogramming — changes in DNA methylation and histone modification — imprints a lasting memory of the injury, locking cells into the maladaptive programme even after the original insult has gone. Around the tubules, peritubular capillaries are lost — capillary rarefaction — producing chronic hypoxia that itself drives fibrosis, while pericytes and fibroblasts transform into matrix-producing myofibroblasts. The convergent endpoint is interstitial fibrosis and tubular atrophy, the histological signature of the failing kidney.

There is also a haemodynamic engine that the CKD volume develops in full. Every AKI episode that leaves fewer functioning nephrons forces the survivors to hyperfilter, and chronic hyperfiltration drives maladaptive hypertrophy and glomerulosclerosis — the same final common pathway by which any nephron loss progresses to CKD. So the transition is both a cellular story of failed repair and senescence and a whole-organ story of lost nephrons and overworked survivors, and the two reinforce each other.

Recovery and weaning from dialysis

For the patient on dialysis, the question is whether and when kidney function will return enough to stop. Recovery is monitored by the trend in creatinine and estimated GFR, the urine output, and the continuing need for renal replacement, and it can be slow — weeks rather than days — sometimes passing through the polyuric phase of Chapter 7. Weaning is guided by recovering clearance and rising urine output: a falling pre-dialysis creatinine and increasing output suggest readiness for a trial off dialysis. There is no perfect predictor, so the art is to avoid two errors — stopping too early, which risks a relapse back onto dialysis, and continuing unnecessarily, which exposes the patient to the dependence and complications that the early-initiation evidence warned against. Some patients recover late, after months, so dialysis dependence early in the course is not always permanent.

The survivorship care gap

Given all this, the most striking failure in AKI care is what happens after discharge: a large proportion of AKI survivors are never followed up for their kidneys at all. They leave hospital with their acute problem resolved and their long-term risk unmanaged, and the AKD window closes unwatched. Closing this gap is the chapter's central therapeutic message. KDIGO recommends evaluating AKI survivors around three months after the episode to assess for resolution, recurrence, and new or progressive CKD, and nephrology follow-up is warranted for those with severe or dialysis-requiring AKI, pre-existing CKD, recurrent episodes, or incomplete recovery. The simple act of arranging follow-up — of treating AKI as the start of a kidney story rather than the end of an admission — is itself an intervention.

Slowing progression and reconciling the drugs

Once a survivor is in follow-up, the work is to slow the transition with the same levers that slow any CKD — the subject of the CKD volume, previewed here. Control blood pressure, reduce proteinuria, and use RAAS blockade judiciously, restarted once the patient has recovered and stabilised rather than left off indefinitely or restarted dangerously early. Emerging evidence supports SGLT2 inhibition for kidney protection in the CKD that follows. Avoid nephrotoxins, manage cardiovascular risk, and treat the complications of any residual CKD. Medication reconciliation after AKI is its own discipline: restart the renin-angiotensin blocker at the right time, never re-expose the patient to the nephrotoxin that caused the episode, and re-dose everything for the function the patient actually recovered to rather than the function they had before. And the survivor should leave understanding their new status — that they have had a kidney attack, that they should avoid nephrotoxins and approach contrast with caution, and that they should hold nephrotoxic drugs during intercurrent illness, the so-called sick-day rules.

Where the evidence is firm, and where it is not

Two things are firm: that AKI raises long-term renal and cardiovascular risk, and that the maladaptive-repair biology described here is real and increasingly well mapped. What is not yet firm is any pharmacological way to interrupt the transition in humans. The preclinical target list is rich — senolytics to clear senescent cells, antifibrotics to interrupt the profibrotic signalling, agents against the developmental pathways and the epigenetic marks — but none has yet earned a place in practice, and the honest position is that, exactly as with established ATN, there is no drug. The evidence-based intervention is therefore the unglamorous one: follow these patients up, control the modifiable risks, avoid the second hit, and let the kidney recover what it can. The biology may one day yield a treatment; until then, survivorship care is the treatment.

Table 15.1 — Recovery categories after AKI

Table 15.2 — Risk factors for the AKI-to-CKD transition

Table 15.3 — Mechanisms of the transition

Table 15.4 — Assessing recovery and weaning from dialysis

Table 15.5 — The post-AKI survivorship bundle

Table 15.6 — The continuum and follow-up timing

Clinical Reasoning

One triad per mechanism the narrative exposed: the physiology, why it matters, and the bedside move.

Safety & Evidence

Panel A — Red flags

Panel B — Never do

Pitfall 1 — 'Recovered, so discharged'

Pitfall 2 — The follow-up gap

Pitfall 3 — Autopilot reconciliation

Pitfall 4 — Premature weaning

Pitfall 5 — Waiting for a drug

Graded statements (by evidence type)

Patient Decisions

Natural-frequency estimates for orientation, from cohort studies; they vary with AKI severity, comorbidity, and follow-up. They convey the size of the transition, expressed per 100 comparable patients.

Apply & Test

Paste-ready notes. Tick the boxes that apply and delete the rest; make the follow-up plan and the medication reconciliation explicit so the survivor is not lost.

Template 1 — AKI recovery and discharge follow-up plan

• Peak AKI stage ___ ; dialysis required: ☐ yes ☐ no; recovery: ☐ complete ☐ partial (new baseline ___ ) ☐ non-recovery.
• Transition risk: ☐ severe/dialysis-requiring ☐ recurrent ☐ incomplete recovery ☐ pre-existing CKD ☐ diabetes/proteinuria.
• Follow-up arranged: ☐ evaluation ~3 months ☐ nephrology referral (if high risk).
• Medication reconciliation: ☐ RAAS restart plan ___ ☐ culprit nephrotoxin flagged/avoided ___ ☐ doses adjusted to recovered eGFR.
• Counselling: ☐ AKI as a risk marker ☐ sick-day rules ☐ contrast caution.
• CKD measures (if residual): ☐ blood pressure ☐ proteinuria ☐ cardiovascular risk (Volume 6).

Template 2 — Dialysis weaning assessment

• Cause of dialysis-requiring AKI ___ ; duration on RRT ___ .
• Recovery signs: ☐ rising urine output (___ mL/day) ☐ falling pre-dialysis creatinine ☐ improving clearance.
• Decision: ☐ continue RRT ☐ trial off RRT (monitor output, creatinine, electrolytes, volume).
• Relapse plan: resume RRT if ___ ; note late recovery possible over months.
• If non-recovery → chronic dialysis pathway and modality education (Books 1–2).